Pre-treatment Metastatic Biopsy: a Step Towards Precision Oncology for Urothelial Cancer

Overview

Journal Nat Rev Urol

Specialty Urology

Date 2024 Oct 30

PMID 39472646

Authors

Niklas Klumper

Alexander Cox

Gottfrid Sjodahl

Florian Roghmann

Christian Bolenz

Arndt Hartmann

Viktor Grunwald

Bishoy M Faltas

Michael Holzel

Markus Eckstein

Affiliations

Soon will be listed here.

Abstract

Early metastatic spread and clonal expansion of individual mutations result in a heterogeneous tumour landscape in metastatic urothelial cancer (mUC). Substantial molecular heterogeneity of common drug targets, such as membranous NECTIN4, FGFR3 mutations, PDL1 or immune phenotypes, has been documented between primary and metastatic tumours. However, translational and clinical studies frequently do not account for such heterogeneity and often investigate primary tumour samples that might not be representative in patients with mUC. We propose this as a potential factor for why many biomarkers for mUC have failed to be integrated into clinical practice. Fresh pre-treatment metastatic biopsies enable the capturing of prevailing tumour biology in real time. The characterization of metastatic tumour samples can improve response prediction to immunotherapy, the anti-NECTIN4 antibody-drug conjugate enfortumab vedotin and the FGFR inhibitor erdafitinib. Routine metastatic biopsy can thus improve the precision of identifying driver druggable alterations, thus improving treatment selection for patients with mUC.

References

Cathomas R, Lorch A, Bruins H, Comperat E, Cowan N, Efstathiou J . The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2021; 81(1):95-103. DOI: 10.1016/j.eururo.2021.09.026. View

Bajorin D, Witjes J, Gschwend J, Schenker M, Valderrama B, Tomita Y . Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384(22):2102-2114. PMC: 8215888. DOI: 10.1056/NEJMoa2034442. View

Powles T, Park S, Voog E, Caserta C, Valderrama B, Gurney H . Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020; 383(13):1218-1230. DOI: 10.1056/NEJMoa2002788. View

Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J . EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol. 2023; 34(11):1047-1054. DOI: 10.1016/j.annonc.2023.08.016. View

van der Heijden M, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M . Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023; 389(19):1778-1789. DOI: 10.1056/NEJMoa2309863. View

Powles T, Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J . Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024; 390(10):875-888. DOI: 10.1056/NEJMoa2312117. View

Meric-Bernstam F, Makker V, Oaknin A, Oh D, Banerjee S, Gonzalez-Martin A . Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2023; 42(1):47-58. PMC: 10730032. DOI: 10.1200/JCO.23.02005. View

Wahida A, Buschhorn L, Frohling S, Jost P, Schneeweiss A, Lichter P . The coming decade in precision oncology: six riddles. Nat Rev Cancer. 2022; 23(1):43-54. DOI: 10.1038/s41568-022-00529-3. View

Loriot Y, Matsubara N, Park S, Huddart R, Burgess E, Houede N . Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023; 389(21):1961-1971. DOI: 10.1056/NEJMoa2308849. View

10.

Clinton T, Chen Z, Wise H, Lenis A, Chavan S, Donoghue M . Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 2022; 41(12):111859. PMC: 9882421. DOI: 10.1016/j.celrep.2022.111859. View

11.

Faltas B, Prandi D, Tagawa S, Molina A, Nanus D, Sternberg C . Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016; 48(12):1490-1499. PMC: 5549141. DOI: 10.1038/ng.3692. View

12.

Gerlinger M, Horswell S, Larkin J, Rowan A, Salm M, Varela I . Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014; 46(3):225-233. PMC: 4636053. DOI: 10.1038/ng.2891. View

13.

Bolenz C, Kunath F, Zengerling F, Wezel F, Schmidt S, Hartmann A . Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials. Urol Int. 2023; 107(5):480-488. DOI: 10.1159/000527879. View

14.

Erlmeier F, Klumper N, Landgraf L, Strissel P, Strick R, Sikic D . Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. Eur Urol. 2022; 83(2):133-142. DOI: 10.1016/j.eururo.2022.10.020. View

15.

Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C . Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2011; 30(6):587-92. PMC: 5015424. DOI: 10.1200/JCO.2010.33.5232. View

16.

Sharma M, Gogia A, Deo S, Mathur S . Role of rebiopsy in metastatic breast cancer at progression. Curr Probl Cancer. 2018; 43(5):438-442. DOI: 10.1016/j.currproblcancer.2018.12.001. View

17.

Hu C, Dignam J . Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precis Oncol. 2020; 3. PMC: 7446374. DOI: 10.1200/PO.19.00086. View

18.

Warrick J, Sjodahl G, Kaag M, Raman J, Merrill S, Shuman L . Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur Urol. 2018; 75(1):18-22. DOI: 10.1016/j.eururo.2018.09.003. View

19.

Choi W, Ochoa A, McConkey D, Aine M, Hoglund M, Kim W . Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol. 2017; 72(3):354-365. PMC: 5764190. DOI: 10.1016/j.eururo.2017.03.010. View

20.

Lamy P, Nordentoft I, Birkenkamp-Demtroder K, Thomsen M, Villesen P, Vang S . Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Res. 2016; 76(19):5894-5906. DOI: 10.1158/0008-5472.CAN-16-0436. View